News | September 10, 2014

FDA Takes Action Against Mammography Facility for Adverse Event

September 10, 2014 — The U.S. Food and Drug Administration (FDA) reports it has revoked the Mammography Quality Standards Act (MQSA) certificate for Advanced Diagnostic Inc., a facility at 2300 W. Peterson Ave. in Chicago. The facility has ceased performing mammography.

On Jan. 31, 2014, the MQSA Hotline received a complaint stating that Advanced Diagnostics Inc. was not providing patients with the results of their mammograms. Upon further investigation by the facility’s certifying agency, the State of Illinois Emergency Management Agency, the complaint was substantiated. As a result, the agency issued an emergency order against the facility for failing to notify patients of their mammography results within the required timeframe as required by the agency and MQSA regulations.

On July 9, 2014, the State of Illinois Emergency Management Agency notified the facility that it must cease performing mammography immediately and that its MQSA certificate was revoked for a period of two years. In addition, the agency assessed a fine of $91,540, which consisted of civil money penalties and fees.

The State of Illinois Emergency Management Agency issued an emergency order that required the facility to conduct mandatory notification of results to the patients. The facility complied with the emergency order.

As part of the MQSA, Congress mandated annual reporting of adverse actions taken against mammography facilities. Congress stipulated that the report be made available to physicians and the general public, and that it should include information useful in evaluating the performance of mammography facilities nationwide.

For more information:

Related Content

Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
Machine Learning Identifies Breast Lesions Likely to Become Cancer
News | Artificial Intelligence | October 18, 2017
A machine learning tool can help identify which high-risk breast lesions are likely to become cancerous, according to a...
Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Joint Venture Partnership Opening 16 New Breast Screening Sites in Texas
News | Breast Imaging | October 04, 2017
HCA Healthcare Gulf Coast Division and Solis Mammography have entered into a joint venture agreement to make breast...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Kubtec Announces Expansion of 3-D Tomosynthesis Technology
News | Digital Radiography (DR) | October 04, 2017
October 4, 2017 — Kubtec announced at the annual conference of the American Association of Pathology Assistants (AAPA
The Siemens Acuson

The Siemens Acuson

Feature | Breast Imaging | October 04, 2017 | By Melinda Taschetta-Millane
According to a new Market Study Report,1 the automated breast ultrasound system (ABUS) market will see a 21 percent...
Overlay Init